Javier SimÃ³n-SÃ;nchez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11873713/publications.pdf

Version: 2024-02-01

52 papers 12,894 citations

36 h-index 52 g-index

56 all docs 56
docs citations

56 times ranked 16040 citing authors

#	Article	IF	CITATIONS
1	A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron, 2011, 72, 257-268.	8.1	3,833
2	Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genetics, 2009, 41, 1308-1312.	21.4	1,745
3	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414
4	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurology, The, 2012, 11, 323-330.	10.2	1,039
5	Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurology, The, 2006, 5, 911-916.	10.2	360
6	Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. American Journal of Human Genetics, 2016, 98, 500-513.	6.2	333
7	Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. Brain, 2017, 140, 3191-3203.	7.6	323
8	Deletion at ITPR1 Underlies Ataxia in Mice and Spinocerebellar Ataxia 15 in Humans. PLoS Genetics, 2007, 3, e108.	3. 5	269
9	Parkinson's disease age at onset genomeâ€wide association study: Defining heritability, genetic loci, and αâ€synuclein mechanisms. Movement Disorders, 2019, 34, 866-875.	3.9	258
10	<i>SNCA</i> variants are associated with increased risk for multiple system atrophy. Annals of Neurology, 2009, 65, 610-614.	5. 3	257
11	The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain, 2012, 135, 723-735.	7.6	249
12	Genome-wide SNP assay reveals structural genomic variation, extended homozygosity and cell-line induced alterations in normal individuals. Human Molecular Genetics, 2007, 16, 1-14.	2.9	211
13	Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Human Molecular Genetics, 2012, 21, 4996-5009.	2.9	176
14	A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release. Lancet Neurology, The, 2007, 6, 414-420.	10.2	175
15	Genome-wide association study confirms extant PD risk loci among the Dutch. European Journal of Human Genetics, 2011, 19, 655-661.	2.8	164
16	A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Human Molecular Genetics, 2013, 22, 1039-1049.	2.9	122
17	The chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiology of Aging, 2012, 33, 209.e3-209.e8.	3.1	115
18	Exome sequencing reveals riboflavin transporter mutations as a cause of motor neuron disease. Brain, 2012, 135, 2875-2882.	7.6	114

#	Article	IF	Citations
19	NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiology of Aging, 2017, 57, 247.e9-247.e13.	3.1	108
20	Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls. Human Molecular Genetics, 2008, 17, 1988-1993.	2.9	106
21	Discovery and functional prioritization of Parkinson's disease candidate genes from large-scale whole exome sequencing. Genome Biology, 2017, 18, 22.	8.8	96
22	Identification of Candidate Parkinson Disease Genes by Integrating Genome-Wide Association Study, Expression, and Epigenetic Data Sets. JAMA Neurology, 2021, 78, 464.	9.0	95
23	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	7.7	90
24	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	7.7	87
25	LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. European Journal of Neuroscience, 2006, 23, 659-666.	2.6	77
26	Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. Lancet Neurology, The, 2016, 15, 585-596.	10.2	77
27	Measures of Autozygosity in Decline: Globalization, Urbanization, and Its Implications for Medical Genetics. PLoS Genetics, 2009, 5, e1000415.	3.5	76
28	The wide genetic landscape of clinical frontotemporal dementia: systematic combined sequencing of 121 consecutive subjects. Genetics in Medicine, 2018, 20, 240-249.	2.4	60
29	C9orf72 is differentially expressed in the central nervous system and myeloid cells and consistently reduced in C9orf72, MAPT and GRN mutation carriers. Acta Neuropathologica Communications, 2016, 4, 37.	5.2	58
30	Lack of replication of association between GIGYF2 variants and Parkinson disease. Human Molecular Genetics, 2008, 18, 341-346.	2.9	55
31	Analysis of Genome-Wide Association Studies of Alzheimer Disease and of Parkinson Disease to Determine If These 2 Diseases Share a Common Genetic Risk. JAMA Neurology, 2013, 70, 1268-76.	9.0	51
32	Genome-wide association studies in neurological disorders. Lancet Neurology, The, 2008, 7, 1067-1072.	10.2	49
33	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€6pecific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	3.9	47
34	Genomewide SNP assay reveals mutations underlying Parkinson disease. Human Mutation, 2008, 29, 315-322.	2.5	46
35	Fine-Mapping, Gene Expression and Splicing Analysis of the Disease Associated LRRK2 Locus. PLoS ONE, 2013, 8, e70724.	2.5	45
36	Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome. Nature Communications, 2021, 12, 7342.	12.8	44

#	Article	IF	CITATIONS
37	The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 666-673.	1.9	43
38	Use of support vector machines for disease risk prediction in genome-wide association studies: Concerns and opportunities. Human Mutation, 2012, 33, 1708-1718.	2.5	42
39	Pilot whole-exome sequencing of a German early-onset Alzheimer's disease cohort reveals a substantial frequency of PSEN2 variants. Neurobiology of Aging, 2016, 37, 208.e11-208.e17.	3.1	38
40	Analysis of SCA-2 and SCA-3 repeats in Parkinsonism: Evidence of SCA-2 expansion in a family with autosomal dominant Parkinson's disease. Neuroscience Letters, 2005, 382, 191-194.	2.1	33
41	Structural genomic variation in ischemic stroke. Neurogenetics, 2008, 9, 101-108.	1.4	32
42	<i>HPCA</i> confirmed as a genetic cause of DYT2â€like dystonia phenotype. Movement Disorders, 2018, 33, 1354-1358.	3.9	31
43	Lack of evidence for a role of genetic variation in TMEM230 in the risk for Parkinson's disease in the Caucasian population. Neurobiology of Aging, 2017, 50, 167.e11-167.e13.	3.1	24
44	A novel homozygous DJ1 mutation causes parkinsonism and ALS in a Turkish family. Parkinsonism and Related Disorders, 2016, 29, 117-120.	2.2	23
45	Variation at GRN 3′-UTR rs5848 Is Not Associated with a Risk of Frontotemporal Lobar Degeneration in Dutch Population. PLoS ONE, 2009, 4, e7494.	2.5	23
46	Cooperative Genome-Wide Analysis Shows Increased Homozygosity in Early Onset Parkinson's Disease. PLoS ONE, 2012, 7, e28787.	2.5	21
47	Comprehensive promoter level expression quantitative trait loci analysis of the human frontal lobe. Genome Medicine, 2016, 8, 65.	8.2	20
48	Biallelic variants in TSPOAP1, encoding the active-zone protein RIMBP1, cause autosomal recessive dystonia. Journal of Clinical Investigation, 2021, 131, .	8.2	18
49	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	3.1	15
50	Accurate prediction of a minimal region around a genetic association signal that contains the causal variant. European Journal of Human Genetics, 2014, 22, 238-242.	2.8	7
51	Parkinson disease GWAS. Neurology, 2015, 84, 966-967.	1.1	7
52	Variation in PARK10 is not associated with risk and age at onset ofÂParkinson's disease in large clinical cohorts. Neurobiology of Aging, 2015, 36, 2907.e13-2907.e17.	3.1	5